Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BAN2401 phase 2 adaptive dose-finding study in early Alzheimer's disease
NL-OMON40054Phase 2Active, not recruiting
- Sponsor
- Eisai Co., Ltd.
- Start
- Jun 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of lecanemab in Alzheimer's disease (AD) (5 arms), sponsored by Eisai Co., Ltd. Primary endpoints: Change from baseline to 12 months in derived Composite Clinical Score and Safety and tolerability of 3 doses and 2 dose regimens of BAN2401. Started Jun 2014; status: active, not recruiting.
02
Drugs
lecanemab
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NL-OMON40054.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON40054.